Valuation: ReShape Lifesciences Inc.

Market Cap 14.46M 12.83M 12.01M 10.89M 20.56M 1.39B 20.71M 144M 56.11M 711M 54.27M 53.11M 2.29B P/E 2026 *
-3.17x
P/E 2027 * -2.59x
Enterprise Value 14.46M 12.83M 12.01M 10.89M 20.56M 1.39B 20.71M 144M 56.11M 711M 54.27M 53.11M 2.29B EV / Sales 2026 *
140x
EV / Sales 2027 * 72.3x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -

Financials

2026 *2027 *
Net sales 103K 91.43K 85.56K 77.55K 146K 9.93M 148K 1.03M 400K 5.07M 387K 378K 16.28M 200K 178K 166K 151K 284K 19.28M 286K 2M 776K 9.84M 751K 735K 31.62M
Net income -4.49M -3.98M -3.73M -3.38M -6.38M -433M -6.43M -44.78M -17.42M -221M -16.85M -16.49M -710M -7.85M -6.96M -6.52M -5.91M -11.16M -756M -11.24M -78.28M -30.45M -386M -29.45M -28.82M -1.24B
Net Debt - -
Logo ReShape Lifesciences Inc.
ReShape Lifesciences Inc. is a weight-loss and metabolic health-solutions company. The Company offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.
Employees
-
Sector
-